The US Food and Drug Administration raised concerns about Lupin Limited’s overall corporate quality system in an 11 June warning letter concerning the company’s Novel Laboratories Inc. facility in Somerset, NJ.
The agency drew a connection between poor manufacturing practices observed at the plant during an eight-week inspection that concluded 5...





